RZLT
Rezolute, Inc.
NASDAQHealthcareBiotechnologyUS
Rating:C+
Company Profile
CEO
Nevan Charles Elam
IPO Date
2013-01-14
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Rezolute, Inc.
CEO
Nevan Charles Elam
IPO Date
2013-01-14
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
| 11,439 |
| $2.99 |
| 4 Mar 2026 | Evans Daron | CFO | F-InKind | Disposed | 11,438 | $2.99 |
| 4 Mar 2026 | Elam Nevan C | director, officer: CEO | F-InKind | Disposed | 27,618 | $2.99 |
| 17 Dec 2025 | Hogenhuis Wladimir | director | P-Purchase | Acquired | 5,650 | $1.69 |
| 17 Dec 2025 | ROBERTS BRIAN KENNETH | Chief Medical Officer | P-Purchase | Acquired | 28,000 | $1.70 |
| 15 Dec 2025 | Evans Daron | CFO | P-Purchase | Acquired | 40,000 | $1.77 |
| 15 Dec 2025 | Evans Daron | CFO | P-Purchase | Acquired | 2,500 | $1.78 |
| 15 Dec 2025 | Evans Daron | CFO | P-Purchase | Acquired | 2,500 | $1.79 |
| 15 Dec 2025 | Elam Nevan C | director, officer: CEO | P-Purchase | Acquired | 32,000 | $1.59 |